Mosunetuzumab

莫妥珠单抗

Report date: 2026/05/22 20:01:29
First In Class

Base Information

Drug NameMosunetuzumab
Drug Alias Name莫妥珠单抗Anti-CD20/CD3 TDBmosunetuzumab-axgbAnti-CD20/CD3 T-cell dependent bispecific antibody(Genentech)CD20xCD3 T-cell engaging bispecific antibody(Genentech) +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD20Anti-CD3
TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3
Therapy Area/IndicationsRichter's SyndromeLupus Erythematosus, SystemicLupus Nephritis +[15] 
Global Approved IndicationsLymphoma, Follicular
Approved Indications in ChinaLymphoma, Follicular
Original Approved Country/TerritoryEU
Original Approved Date2022/06/03
Country/TerritoryBelgiumCanadaUnited States +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdRoche Pharma (Schweiz) AgF. Hoffmann-La Roche Ag +[12] 
Inactive CompaniesN/A
Active IndicationsRichter's SyndromeLupus Erythematosus, SystemicLupus Nephritis +[13] 
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG